Latest News on INGN

Financial News Based On Company


Advertisement
Advertisement

What You Need To Know About The Inogen, Inc. (NASDAQ:INGN) Analyst Downgrade Today

https://simplywall.st/stocks/us/healthcare/nasdaq-ingn/inogen/news/what-you-need-to-know-about-the-inogen-inc-nasdaqingn-analys
Inogen, Inc. (NASDAQ:INGN) has experienced an analyst downgrade, leading to significant cuts in revenue estimates for 2027. Analysts now forecast a 13% decline in sales, a stark contrast to previous optimistic predictions. This revised outlook, coupled with an anticipated accelerated decline in revenue compared to industry growth, suggests a more cautious sentiment towards Inogen.

Inogen 3Q 2026: Revenue $77.19M, EPS ($0.61) — 10-Q Summary

https://www.tradingview.com/news/tradingview:70f6dfde73570:0-inogen-3q-2026-revenue-77-19m-eps-0-61-10-q-summary/
Inogen (INGN) reported a 2.4% year-over-year revenue decline to $77.19 million in Q3 2026, with a widened net loss of $16.16 million, or ($0.61) EPS, largely due to a goodwill impairment charge. The decrease was attributed to lower international demand, especially from European partners, and reduced average selling prices and channel mix, despite stronger U.S. sales of portable units. The company also completed the sale of its U.S. oxygen rental business in November 2026.

Inogen Targets $20 Million in Savings, Projects Q4 Revenue of $65 Million to $68 Million

https://www.tokenpost.com/news/business/51813
Inogen, Inc. aims to achieve $20 million in annualized cost savings by the end of 2027 and projects fourth-quarter revenue between $65 million and $68 million. The company expects $10 million in annualized savings by the end of 2026, with full-year 2026 continuing-operations revenue estimated at $298 million to $301 million. Despite international sales weakness, management anticipates accelerating U.S. growth to offset it, projecting an adjusted net loss from continuing operations of $7 million to $8 million for the full year.

Inogen Q3 GAAP revenue dips 2.4% to USD 77.2M

https://medicalbuyer.co.in/inogen-q3-gaap-revenue-dips-2-4-to-usd-77-2m/
Inogen, Inc. announced its financial results for the third quarter of 2026, reporting a 2.4% decrease in GAAP total revenue to $77.2 million. The company experienced a GAAP net loss per diluted share of $0.56, compared to $0.13 in the prior-year period. Inogen also updated its financial outlook for Q4 and full-year 2026, expecting revenues from continuing operations in the range of $65 million to $68 million for Q4, and $298 million to $301 million for the full year.

What Inogen (INGN) Said on Its Q3 Earnings Call

https://es.tradingview.com/news/marketbeat:531c8f3c6094b:0-what-inogen-ingn-said-on-its-q3-earnings-call/
Inogen (INGN) reported a decline in third-quarter revenue, reaching $77.2 million, primarily due to reduced spending from large European customers, despite a return to growth in U.S. sales. The company announced a $20 million annualized cost-reduction program and completed the sale of its U.S. oxygen rental business to simplify operations. Inogen also provided a Q4 revenue forecast of $65 million to $68 million and a full-year outlook anticipating an adjusted net loss of $7 million to $8 million.
Advertisement

Inogen’s new CEO sets sights on ‘simpler’ company

https://www.hmenews.com/article/inogen-s-new-ceo-sets-sights-on-simpler-company
Andy Reding, Inogen's new President and CEO, aims to simplify the company, strengthen execution, and return it to profitable growth. Key initiatives include the divestiture of its U.S. oxygen rental business to Rotech Healthcare for up to $24.8 million and implementing an additional $20 million cost-reduction program. Inogen reported a 3.8% increase in U.S. sales in the third quarter, its first year-over-year growth since Q4 2024.

Inogen Inc (INGN) Q3 2026 Earnings Call Highlights: US Sales Return to Growth as Cost Cuts ...

https://ca.finance.yahoo.com/news/inogen-inc-ingn-q3-2026-131420969.html
Inogen Inc. (INGN) reported mixed Q3 2026 results, with US sales returning to growth at 3.8% driven by distributor demand and new products, and the divestiture of its US oxygen rental business streamlining operations. However, total revenue decreased 2.4% due to a 9% decline in international sales, and the company announced an additional $20 million annualized cost savings program to accelerate profitability. Despite a GAAP loss, Inogen maintains a strong balance sheet and has increased its share repurchase authorization.

Inogen Q3 2026 Revenue Falls as Impairment Widens Loss

https://www.tradingkey.com/news/presentation/262291680-
Inogen Inc. (NASDAQ: INGN) reported a 2.4% year-over-year revenue decline to $77.2 million in Q3 2026, primarily due to a 9.0% drop in international sales which offset a 3.8% recovery in U.S. revenue. The company's GAAP operating loss significantly widened to $15.6 million and loss from continuing operations to $14.8 million, or $0.56 per share, largely due to a $10.6 million impairment charge. Adjusted operating loss also increased, reflecting narrower gross margins and higher R&D expenses, with no forward financial guidance provided.

What Inogen (INGN) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:531c8f3c6094b:0-what-inogen-ingn-said-on-its-q3-earnings-call/
Inogen (INGN) reported a 2.4% decline in third-quarter revenue to $77.2 million, primarily due to reduced spending by large European customers, despite a return to growth in U.S. sales. The company announced a $20 million annualized cost-reduction program and completed the sale of its U.S. oxygen rental business to streamline operations and focus on higher-priority opportunities. Inogen also forecasted Q4 revenue of $65 million to $68 million and a full-year adjusted net loss of $7 million to $8 million.

Inogen Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62958292/inogen-q3-2026-earnings-call-transcript
Inogen reported third-quarter 2026 revenue of $77.2 million, a 2.4% decrease year-over-year, despite U.S. sales growing 3.8%. The company divested its U.S. Oxygen rental business for $24.8 million to streamline operations and focus on core strengths, while also announcing a $20 million cost savings program for improved profitability. Inogen anticipates Q4 2026 revenue between $65 million and $68 million, with U.S. sales growth expected to mitigate international softness.
Advertisement

Inogen Inc earnings missed by $0.42, revenue fell short of estimates

https://www.investing.com/news/earnings/inogen-inc-earnings-missed-by-042-revenue-fell-short-of-estimates-5005847
Inogen Inc (NASDAQ: INGN) reported third-quarter EPS of $-0.56, missing analyst estimates by $0.42. Revenue for the quarter also fell short, coming in at $77.19M against a consensus estimate of $92.25M. The company's stock price has shown an 11.90% increase over the last three months but is down -3.70% over the past 12 months.

Inogen names Andy Reding as CEO, replacing Kevin Smith By Investing.com

https://uk.investing.com/news/stock-market-news/inogen-names-andy-reding-as-ceo-replacing-kevin-smith-93CH-4962418
Inogen Inc. announced that its board of directors has appointed Andy Reding as president and chief executive officer, replacing Kevin Smith. Reding, who joined the company as COO in July, brings over 30 years of medical technology experience and previously served as chief commercial officer of Viant Medical. The company stated this leadership transition is aimed at strengthening execution and expanding access to its respiratory solutions.

Inogen, Inc. (INGN) Seasonal returns chart

https://uk.finance.yahoo.com/quote/INGN/seasonality/
The article provides a seasonal returns chart for Inogen, Inc. (INGN) showing the average monthly price return from 2016 to 2026. It indicates the stock's current real-time price on NasdaqGS along with a 4.81% increase. The page also offers various financial data and analysis options for the company.

Inogen, Inc Estimates – NASDAQ:INGN

https://www.tradingview.com/symbols/NASDAQ-INGN/financials-estimates/
This article provides access to the financial estimates for Inogen, Inc (NASDAQ: INGN) via TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Inogen schedules November 5 results: two analysts cover Inogen stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/inogen-schedules-november-5-results-two-analysts-cover-inogen-stock/70377248
Inogen, Inc. (INGN) is scheduled to release its third-quarter 2026 financial results on November 5, 2026, at 5:00 p.m. ET. The company reported a 3.00 percent year-over-year revenue increase to USD 95.10 million in the second quarter of 2026, with international sales growing by 15.00 percent while U.S. sales declined by 2.00 percent. As of October 20, 2026, Inogen had a market capitalization of USD 178.1 million.
Advertisement

Price to earnings forward of Inogen, Inc. – LSX:A1XB32

https://www.tradingview.com/symbols/LSX-A1XB32/financials-statistics-and-ratios/price-earnings-fwd/
This article provides financial information for Inogen, Inc. (LSX:A1XB32), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of publication. The data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr.

Needham keeps USD 12.00 target for Inogen stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/needham-keeps-usd-12-00-target-for-inogen-stock/70351418
Needham has reiterated its Buy rating and USD 12.00 price target for Inogen (INGN) as of October 1, 2026. This target represents a 92% upside from the stock's last traded price of USD 6.25 on October 16, 2026. Inogen reported Q2 2026 revenue of USD 95.08 million and is scheduled to announce Q3 2026 results on November 5, 2026.

Inogen to report Q3FY26 results on November 5, 2026

https://scanx.trade/stock-market-news/companies/inogen-report-q3fy26-results-november-5-2026/53630023
Inogen, Inc. announced it will release its third-quarter 2026 financial results after market close on November 5, 2026, followed by a conference call at 5:00 pm Eastern Time. A replay of the call will be available until November 12, 2026. The medical technology company specializes in respiratory products and uses its Investor Relations website for material non-public information.

What Inogen Investors Missed Before The Fall

https://simplywall.st/stocks/us/healthcare/nasdaq-ingn/inogen/news/what-inogen-investors-missed-before-the-fall
Inogen's recent Q2 2026 financial report showed revenue of US$95.084 million and a reduced net loss, yet investors are down 24.3% over the past year. The article highlights the importance of net margin improvement over just revenue growth for a company whose thesis relies on margin repair. It discusses how the current trading price of US$6.34 reflects a need for product launches and digital health efforts to translate into significantly higher margins.

Full Transcript: Inogen Q2 2026 Earnings Call

https://www.benzinga.com/news/26/10/62315447/full-transcript-inogen-q2-2026-earnings-call
Inogen reported a 3% year-over-year revenue increase to $95.1 million in Q2 2026, driven by strong international growth and new products, despite a 2% decline in U.S. sales. The company raised its adjusted EBITDA guidance to $4 million for the full year 2026, while lowering its revenue guidance due to U.S. channel mix shifts and international distributor inventory management. Inogen continues to invest in product innovation, particularly with its Voxi and Aurora products, and is advancing regulatory processes in China for long-term growth opportunities.
Advertisement

Inogen stock sharpens its focus with a USD 25 million sale

https://www.ad-hoc-news.de/boerse/news/nebenwerte/inogen-stock-sharpens-its-focus-with-a-usd-25-million-sale/70260787
Inogen (INGN) is strategically selling its U.S. oxygen rental assets to Rotech for up to $25 million to refocus its business on product sales and distribution. This move, accompanied by a long-term supply agreement, is expected to enhance revenue growth and adjusted operating income. Analysts maintain a "Buy" rating with a $12.00 price target, significantly above its current trading price, as the company aims to offset declining rental revenue with faster product growth.

INGN: Inogen Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/INGN
This article provides an overview of Inogen Inc. (INGN), a medical technology company specializing in respiratory products. It includes current stock price data, key financial fundamentals like market cap and P/E ratio, and recent news such as upcoming earnings reports and a business divestiture. The article also features sentiment data and social media discussions related to the company.

Inogen stock faces a strategic reset after rental sale

https://www.ad-hoc-news.de/boerse/news/corporate-news/inogen-stock-faces-a-strategic-reset-after-rental-sale/70223812
Inogen has agreed to sell its U.S. oxygen rental business to Rotech Healthcare for up to $25 million, a strategic divestiture aimed at improving business mix and profitability. The rental unit generated $24.3 million in revenue in the first half of 2026 and will be reported as discontinued operations from Q3 2026. Needham maintains a Buy rating and a $12.00 price target on Inogen stock, suggesting significant upside from its current price after the announced sale.

Inogen Inc (6IO.DU) Analyst Insights, Price Targets & Recommendations

https://ca.finance.yahoo.com/quote/6IO.DU/analyst-insights/
This article provides a summary of analyst insights, price targets, and recommendations for Inogen Inc (6IO.DU). It lists recent actions such as initiations, upgrades, and reiterations from various brokerage firms. The stock was trading at 5.15 EUR, up 0.98%, at market close on October 5th.

Inogen to sell U.S. oxygen rental biz to Rotech Healthcare

https://www.hmenews.com/article/inogen-to-sell-u-s-oxygen-rental-biz-to-rotech-healthcare
Inogen has announced a definitive agreement to sell its U.S. oxygen rental business to Rotech Healthcare for an estimated cash consideration of up to $25 million. This divestiture is part of Inogen's strategy to streamline its operations, focusing on respiratory innovation and partnering with HME providers for broader product distribution. The company anticipates improved profitability and growth by concentrating on its core competencies while ensuring continued patient access to its oxygen concentrators through Rotech's network.
Advertisement

Inogen sharpens business focus with $25m oxygen rental unit divestment

https://finance.yahoo.com/healthcare/articles/inogen-sharpens-business-focus-25m-115820972.html
Inogen has agreed to sell its US oxygen rental business to Rotech Healthcare for up to $25 million to refine its focus on product innovation. The deal, expected to close by Q4 2026, includes a long-term supply agreement with Rotech to expand access to Inogen's oxygen concentrators. This strategic move follows declining revenues in the rental segment and aims to strengthen Inogen's business and financial profile amidst rising COPD cases.

Inogen to sell U.S. oxygen rental business to Rotech for $25M

https://www.investing.com/news/company-news/inogen-to-sell-us-oxygen-rental-business-to-rotech-for-25m-93CH-4925851
Inogen Inc. announced an agreement to sell its U.S. oxygen rental business to Rotech Healthcare for up to $25 million in cash, with the transaction expected to close in the fourth quarter of 2026. Following the divestiture, Inogen will concentrate on respiratory innovation and partner with home medical equipment providers for distribution, while also increasing its share repurchase authorization by $15 million to a total of $45 million. This strategic move aims to strengthen Inogen's business and financial profile, allowing it to focus on core innovation.

Inogen to sell U.S. oxygen rental business to Rotech for $25M

https://uk.investing.com/news/stock-market-news/inogen-to-sell-us-oxygen-rental-business-to-rotech-for-25m-93CH-4890302
Inogen Inc. announced its plan to sell its U.S. oxygen rental business to Rotech Healthcare for up to $25 million in cash, with the transaction expected to close in Q4 2026. This divestiture will allow Inogen to concentrate on respiratory innovation and partner with home medical equipment providers for distribution, while also maintaining its direct-to-consumer sales channel. The company's Board of Directors approved a $15 million increase to its share repurchase authorization, bringing the total to $45 million, set to expire on June 30, 2028.

Inogen plans to sell its oxygen rentals to Rotech; patients can still buy its products directly.

https://www.stocktitan.net/news/INGN/inogen-announces-divestiture-of-its-u-s-oxygen-rental-business-to-latnrz9hbdfq.html
Inogen has announced the divestiture of its U.S. oxygen rental business to Rotech Healthcare for an estimated cash consideration of up to $25 million. This strategic move aims to streamline Inogen's business model, focusing on higher revenue growth and adjusted operating income, while partnering with home medical equipment providers to expand product access. Inogen will also enter a long-term supply agreement with Rotech and intends to present the rental business as discontinued operations starting in Q3 2026, with an increased share repurchase authorization of $15 million.

Inogen to Sell U.S. Oxygen Rental Assets to Rotech Healthcare for Up to $24.8 Million

https://www.tradingview.com/news/tradingview:127204414a6f4:0-inogen-to-sell-u-s-oxygen-rental-assets-to-rotech-healthcare-for-up-to-24-8-million/
Inogen has entered into an Asset Purchase Agreement to sell its U.S. oxygen rental business assets to Rotech Healthcare for an estimated $24.8 million. The payment will be made in six installments and is subject to post-closing reconciliation. This transaction, which includes inventory and patient records, aims to streamline Inogen's portfolio and is subject to customary closing conditions.
Advertisement

Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech

https://www.businesswire.com/news/home/20260930407827/en/Inogen-Announces-Divestiture-of-Its-U.S.-Oxygen-Rental-Business-to-Rotech
Inogen, Inc. announced its divestiture of its U.S. oxygen rental business to Rotech Healthcare for up to $25 million and signed a new long-term supply agreement with Rotech. This strategic move aims to streamline Inogen's commercial model, drive higher revenue growth, and improve adjusted operating income. The transaction is expected to close in Q4 2026, and Inogen's Board has approved a $15 million increase to its share repurchase authorization.

Trading the Move, Not the Narrative: (INGN) Edition

https://news.stocktradersdaily.com/news_release/23/Trading_the_Move,_Not_the_Narrative:_INGN_Edition_092526040402_1790323442.html
This article analyzes Inogen Inc (NASDAQ: INGN), noting a near-term neutral sentiment suggesting a pause in its mid and long-term weakness. It highlights an exceptional 75.0:1 risk-reward setup targeting a 15.3% gain against a 0.2% risk, and provides three AI-generated trading strategies for different risk profiles. The strategies include position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones.

Inogen Portable Oxygen Concentrator(s) Review 2026

https://www.ncoa.org/product-resources/oxygen/inogen-review/
This article reviews Inogen's portable oxygen concentrators for 2026, focusing on the Inogen Rove 4 and Rove 6 models. It highlights their lightweight design, FAA approval for air travel, battery life, and pulse-dose delivery system, noting that they may not be suitable for those needing continuous-flow oxygen. The review also covers pricing, pros and cons of each model, and customer feedback.

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

https://www.easternprogress.com/inogen-cuts-2026-revenue-outlook-as-u-s-channel-pressure-persists/article_ec4ccefd-f59d-5548-9a6e-f296ef3913d7.html
Inogen (INGN) has reduced its 2026 revenue outlook due to persistent U.S. channel pressure, despite improved profitability and international growth. The company expects 2026 revenues between $355 million and $361 million, a decrease from previous projections, primarily driven by a shift in the U.S. oxygen market toward portable oxygen concentrators initially supplied by home medical equipment providers, impacting Inogen's direct sales. While international sales and new products like the Voxi stationary oxygen concentrator and Aurora CPAP masks offer some offsets, the company is reviewing its cost structure to align spending with strategic priorities.

Inogen stock trades as Nasdaq reaches a new high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/inogen-stock-trades-as-nasdaq-reaches-a-new-high/70162926
Inogen stock (INGN) is trading against a new record high set by the Nasdaq Composite on September 23, 2026. While the strong growth-stock environment can influence trading, the article emphasizes that Inogen's operating figures, such as revenue and earnings, remain the primary factors for assessing the medical-device company's performance. Investors should focus on company-specific data and compare current results to prior-year periods for a true measure of progress.
Advertisement

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

https://www.easternprogress.com/should-investors-buy-inogen-as-low-valuation-meets-execution-risk/article_f4c1fe31-b1b4-5eab-853a-c8fd9e0db2cf.html
Inogen (INGN) faces an interesting investment dilemma with a low valuation and improved margins, balanced against significant execution risks. While international sales are strong and the balance sheet is debt-free, the company struggles with declining U.S. direct sales and rentals. Investors are advised to be patient and monitor the company's ability to offset traditional channel weaknesses with business-to-business growth and new product offerings.

Inogen Inc (NASDAQ: INGN) Grants 1,500 Shares to Chief Accounting Officer Mary E Wright at $5.33 Each

https://kalkinemedia.com/us/news/announcements/inogen-inc-nasdaq-ingn-grants-1500-shares-to-chief-accounting-officer-mary-e-wright-at-533-each
Inogen Inc. (NASDAQ: INGN) has granted 1,500 shares to its Chief Accounting Officer, Mary E Wright, at a price of $5.33 per share. This transaction, executed on September 1, 2026, under code A, increases her total ownership in the company to 20,629 shares. The disclosure provides transparency into her ownership stake and the details of the equity award.

Inogen (INGN) accounting chief adds 1,500 shares in stock purchase

https://www.stocktitan.net/sec-filings/INGN/form-4-inogen-inc-insider-trading-activity-4a859abbf965.html
Inogen's Vice President and Chief Accounting Officer, Mary E. Wright, acquired 1,500 shares of the company's common stock on September 1, 2026, through its 2014 Employee Stock Purchase Plan. This purchase increased her direct holdings to 20,629 shares. The acquisition was made at a price of $5.33 per share.

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67

https://www.moomoo.com/news/post/74563316/inogen-inc-nasdaq-ingn-released-earnings-last-week-and-analysts
Following Inogen's recent earnings report, analysts have significantly increased their price targets for the company, now averaging US$12.67 per share. This upgrade reflects a more optimistic outlook from the market, with the consensus price target rising by 21% from previous estimates. Despite the positive analyst sentiment, the article highlights that the stock has experienced a 21% decline over the past week.

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:82732d933094b:0-here-s-why-you-should-retain-inogen-stock-in-your-portfolio-for-now/
Inogen, Inc. (INGN) is positioned for growth due to strong demand for portable oxygen concentrators (POCs), an expanding B2B market, and international expansion. Despite these positive indicators, the company faces risks such as U.S. revenue pressure from channel shifts, volatility due to international distributor inventory timing, and clinical/reimbursement challenges for its Simeox technology. Inogen's valuation appears attractive with a P/S ratio of 0.4 compared to the industry's 2.7, and analysts project continued business improvements.
Advertisement

Top 3 Health Care Stocks That Could Blast Off This Month

https://www.sahmcapital.com/news/content/top-3-health-care-stocks-that-could-blast-off-this-month-2026-08-19
This article identifies three oversold healthcare stocks—Veracyte Inc (VCYT), Akso Health Group (AHG), and Inogen Inc (INGN)—that could present buying opportunities. These companies have a Relative Strength Index (RSI) near or below 30, indicating they may be undervalued. Recent news affecting each company, including earnings and R&D initiatives, are highlighted.

CPAP Store USA Adds New Inogen Aurora CPAP Mask Line

https://sleepreviewmag.com/sleep-treatments/therapy-devices/cpap-pap-devices/cpap-store-usa-inogen-aurora-cpap-mask-line/
CPAP Store USA has launched Inogen's new Aurora CPAP Mask Collection, becoming the first authorized online and in-store retailer for these non-magnetic masks. This expansion introduces three mask interfaces—F1 Full Face, N1 Nasal, and P1 Nasal Pillows—offering greater choice and comfort for CPAP and BiPAP users. The move signifies a notable expansion for both companies, with Inogen entering sleep therapy and CPAP Store USA broadening its respiratory care offerings.

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67

https://simplywall.st/stocks/us/healthcare/nasdaq-ingn/inogen/news/inogen-inc-nasdaqingn-released-earnings-last-week-and-analys-1
Inogen, Inc. (NASDAQ:INGN) reported quarterly results last week, showing revenues of US$95m and losses of US$0.14 per share, which were better than analyst expectations. Following the earnings, analysts maintained their loss per share estimates for 2026 but downgraded revenue forecasts, expecting Inogen to grow slower than the broader industry. Despite the revenue downgrade, analysts lifted their price target for Inogen by 8.6% to US$12.67 per share, suggesting an improvement in the company's intrinsic value.

Dimensional Fund Advisors LP Reduces Position in Inogen, Inc $INGN

https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-reduces-position-in-inogen-inc-ingn-2026-08-13/
Dimensional Fund Advisors LP significantly reduced its stake in Inogen, Inc. by 28.3% in the first quarter, selling over 200,000 shares but still retaining a substantial holding. Despite this reduction, other institutional investors have increased their positions, and Inogen's stock holds a "Moderate Buy" consensus rating from analysts, even after a reiterated "sell" rating from Weiss Ratings. The company recently reported a narrower-than-expected quarterly loss, though revenue slightly missed forecasts, with analysts anticipating a full-year loss of $0.77 per share.

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

https://au.finance.yahoo.com/news/inogen-cuts-2026-revenue-outlook-162300728.html
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, specifically a decline in direct sales and rentals, despite strong international growth and improved profitability. The company expects 2026 revenues to be between $355 million and $361 million, a reduction from previous estimates. Inogen is focusing on business-to-business efforts and new products like the Voxi stationary oxygen concentrator to adapt to the changing market.
Advertisement

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

https://www.tradingview.com/news/zacks:a13479625094b:0-should-investors-buy-inogen-as-low-valuation-meets-execution-risk/
Inogen (INGN) trades at a significant discount compared to its industry peers, driven by improved Q2 2026 margins and strong international demand. While the company boasts a debt-free balance sheet and expanding respiratory offerings, persistent weakness in U.S. direct sales and rentals presents execution risks. The current low valuation combined with mixed operational signals suggests a cautious "hold" stance for investors.

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

https://www.tradingview.com/news/zacks:40f693119094b:0-inogen-cuts-2026-revenue-outlook-as-u-s-channel-pressure-persists/
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, despite experiencing better profitability and international growth in the second quarter. The company is facing a shift in the U.S. oxygen market towards portable oxygen concentrators as initial therapy, impacting its direct-to-consumer sales, while international sales continue to grow. Inogen is expanding its business-to-business efforts and new product offerings like Voxi stationary oxygen concentrators and Aurora CPAP masks to offset these challenges.

Inogen Launches First CPAP Mask Portfolio

https://respiratory-therapy.com/products-treatment/monitoring-treatment/therapy-devices/inogen-launches-first-cpap-mask-portfolio/
Inogen Inc. has launched its Aurora CPAP mask portfolio in the United States, marking its entry into the obstructive sleep apnea market. This expansion aims to leverage existing distribution channels to offer a variety of mask designs—F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows—to meet diverse patient needs. The company reports high patient satisfaction with the comfort and performance of the new masks, which are seen as a key growth catalyst in Inogen's strategy to become a broader home healthcare respiratory solutions provider.

Inogen Launches Voxi 5 Stationary Oxygen Concentrator

https://respiratory-therapy.com/products-treatment/monitoring-treatment/therapy-devices/inogen-launches-voxi-5-stationary-oxygen-concentrator/
Inogen Inc. has launched the Voxi 5, a new stationary oxygen concentrator (SOC) developed with Yuwell Medical, to expand access to oxygen therapy for long-term care patients in the US. This device provides 1-5 liters per minute of continuous flow oxygen, offering a compact and mobile solution designed for affordability and to complement Inogen's portable oxygen concentrator line. The Voxi 5 aims to serve price-sensitive customers and those needing additional units for multi-room use, reinforcing Inogen's commitment to accessible respiratory care.

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

https://sg.finance.yahoo.com/news/inogen-q2-earnings-beat-estimates-165400227.html
Inogen reported breakeven earnings for Q2 2026, beating estimates, with revenues of $95.1 million, up 3% year over year, driven by strong international demand and new products. However, the company cut its full-year 2026 revenue guidance to $355-$361 million due to continued U.S. sales channel mix pressure. Despite this, Inogen is focused on expanding its respiratory care portfolio and expects to launch at least one new product annually.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement